Sun Jingyao, Hou Zhaoyao, Xia Tian, Liu Chang, Huang Qiangwen, Wei Li
Department of Thoracic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Department of Thoracic Surgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Interdiscip Cardiovasc Thorac Surg. 2025 May 6;40(5). doi: 10.1093/icvts/ivae097.
To explore whether portable budesonide-formoterol powder inhalation can ameliorate cough symptoms and improve pulmonary function recovery in patients who underwent thoracoscopic lung surgery.
Clinical data of patients who underwent thoracoscopic pulmonary resection at Henan Provincial People's Hospital between December 2022 and May 2023 were extracted. To evaluate the impact of continuous postoperative use of portable budesonide-formoterol powder inhalation, patients were divided into two groups: the control group and the case group. Next, we compared the Leicester cough score and pulmonary function indexes of the patients before surgery, 1 month and 6 months after the operation.
A total of 188 cases were included, and the baseline demographic characteristics of both groups were well-balanced. The internal consistency of the Mandarin Chinese version of the Leicester Cough Questionnaire (LCQ-MC) scale, as indicated by Cronbach's α coefficients, was all greater than 0.8, and there was no significant difference in LCQ-MC scores between the two groups before the operation (Z = -1.173, P = 0.241). Postoperatively, the LCQ-MC score in the case group was significantly higher than that in the control group (18.66 vs 16.79, P < 0.01), with a notable statistically significant difference in the reduction of LCQ-MC scores between the two groups (1.32 vs 3.30, P < 0.01). Analysis of lung function revealed that patients in the case group exhibited significant improvements in FEV1/FVC, FVC, FEV1, PEF, MMEF75/25, MVV, DLCO and the RV/TLC indexes compared to the control group (P < 0.01).
Portable budesonide-formoterol powder inhalation can alleviate cough symptoms and promote pulmonary function recovery in patients following thoracoscopic lung surgery.
探讨便携式布地奈德-福莫特罗粉吸入剂能否改善胸腔镜肺手术患者的咳嗽症状并促进肺功能恢复。
提取2022年12月至2023年5月在河南省人民医院接受胸腔镜肺叶切除术患者的临床资料。为评估术后持续使用便携式布地奈德-福莫特罗粉吸入剂的影响，将患者分为两组：对照组和病例组。接下来，我们比较了患者术前、术后1个月和6个月的莱斯特咳嗽评分和肺功能指标。
共纳入188例患者，两组的基线人口统计学特征均衡。莱斯特咳嗽问卷中文版（LCQ-MC）量表的内部一致性，以Cronbach's α系数表示，均大于0.8，两组术前LCQ-MC评分无显著差异（Z = -1.173，P = 0.241）。术后，病例组的LCQ-MC评分显著高于对照组（18.66对16.79，P < 0.01），两组LCQ-MC评分降低幅度有显著统计学差异（1.32对3.30，P < 0.01）。肺功能分析显示，与对照组相比，病例组患者的FEV1/FVC、FVC、FEV1、PEF、MMEF75/25、MVV、DLCO和RV/TLC指标有显著改善（P < 0.01）。
便携式布地奈德-福莫特罗粉吸入剂可减轻胸腔镜肺手术后患者的咳嗽症状并促进肺功能恢复。
